Aberrant acetylated modification of FGF21-KLB signaling contributes to hepatocellular carcinoma metastasis through the β-catenin pathway

被引:2
作者
Xia, Jinkun [1 ,2 ]
Zhu, Zhengyi [1 ,2 ]
Wen, Gaolin [3 ]
Chen, Yuyan [1 ,2 ]
An, Ran [1 ,2 ]
Xia, Senzhe [1 ]
Guan, Wenxian [2 ,4 ,6 ]
Ren, Haozhen [1 ,2 ,4 ,5 ]
机构
[1] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Dept Hepatobiliary Surg,Med Sch, Nanjing 210008, Jiangsu, Peoples R China
[2] Nanjing Univ, Hepatobiliary Inst, Med Sch, Nanjing 210008, Jiangsu, Peoples R China
[3] Nanjing Univ Chinese Med, Nanjing Drum Tower Hosp, Affiliated Hosp, Dept Gen Surg,Med Sch,Clin Coll, Nanjing 210008, Jiangsu, Peoples R China
[4] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Dept Gen Surg,Med Sch, Nanjing 210008, Jiangsu, Peoples R China
[5] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Dept Hepatobiliary Surg,Med Sch, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
[6] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Dept Gen Surg,Med Sch, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
beta-klotho; fibroblast growth factor 21; hepatocellular carcinoma; metastasis; epigenetic modification; HISTONE DEACETYLASE INHIBITORS; DOWN-REGULATION; EXPRESSION; CANCER; TRANSITION; KLOTHO;
D O I
10.3892/ijo.2023.5539
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
beta-Klotho (KLB) is a vital element of the fibroblast growth factor (FGF) receptor complex and acts as a co-receptor to facilitate the binding of FGF19 and FGF21 to the FGFRs on the target cells. The present study aimed to determine the contribution of FGF21-KLB signaling to hepatocellular carcinoma (HCC) metastasis. KLB expression was measured in HCC tissues and cell lines using western blot and reverse transcription-quantitative PCR. Furthermore, the proliferation, apoptosis and metastasis capacity of KLB-knockdown Huh7 cells (human HCC cell line) were assessed by Cell Counting Kit-8 assay, 5-ethynyl-2'-deoxyuridine assay, flow cytometry, wound-healing assay and Transwell assay. Enrichment analysis was used to explore the underlying regulatory mechanisms of KLB. The metastasis potential of human HCC cells in the context of FGF21 with or without KLB inhibition was determined in vitro and in vivo. Acetylated modification of KLB was determined using a co-immunoprecipitation assay. The results indicated a significant upregulation of KLB in HCC tissues compared with the corresponding normal tissues. In addition, KLB expression was closely associated with HCC metastasis. Migration and invasion assays revealed that KLB knockdown promoted the metastatic capability of HCC cells. Gene set variation analysis and subsequent mechanistic investigations revealed that KLB is the upstream regulatory factor of beta-catenin signaling. Furthermore, FGF21 was indicated to suppress HCC metastasis by inhibiting beta-catenin signaling-driven epithelial-mesenchymal transition ( EMT), while KLB knockdown and simultaneous FGF21 overexpression promoted HCC cell motility. Histone deacetylase 3 (HDAC3) was further characterized as the potential deacetylase for KLB. Furthermore, the results revealed that HDAC3 inhibitor-mediated acetylated modification led to KLB inactivation, resulting in the blockade of FGF21-KLB signaling, which further triggered the expression of EMT induction-related genes in Huh7 cells. In conclusion, the present study demonstrated that aberrant acetylated modification of KLB inhibited FGF21-KLB signaling, thereby promoting beta-catenin signaling-driven EMT and HCC metastasis.
引用
收藏
页数:13
相关论文
共 46 条
  • [1] Epigenetic therapy as a novel approach in hepatocellular carcinoma
    Anestopoulos, Ioannis
    Voulgaridou, Georgia Persephoni
    Georgakilas, Alexandros G.
    Franco, Rodrigo
    Pappa, Aglaia
    Panayiotidis, Mihalis I.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2015, 145 : 103 - 119
  • [2] Epigenetics in cancer: Fundamentals and Beyond
    Biswas, Subhankar
    Rao, C. Mallikarjuna
    [J]. PHARMACOLOGY & THERAPEUTICS, 2017, 173 : 118 - 134
  • [3] Histone deacetylase 3 aberration inhibits Klotho transcription and promotes renal fibrosis
    Chen, Fang
    Gao, Qi
    Wei, Ai
    Chen, Xingren
    Shi, Yujun
    Wang, Hongwei
    Cao, Wangsen
    [J]. CELL DEATH AND DIFFERENTIATION, 2021, 28 (03) : 1001 - 1012
  • [4] Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4
    Chen, Jie
    Du, Feng
    Dang, Yunzhi
    Li, Xiaowei
    Qian, Meirui
    Feng, Weibo
    Qiao, Chenyang
    Fan, Daiming
    Nie, Yongzhan
    Wu, Kaichun
    Xia, Limin
    [J]. HEPATOLOGY, 2020, 71 (05) : 1712 - 1731
  • [5] Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver
    Cui, Guozhen
    Martin, Robert C.
    Jin, Hang
    Liu, Xingkai
    Pandit, Harshul
    Zhao, Hengjun
    Cai, Lu
    Zhang, Ping
    Li, Wei
    Li, Yan
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [6] Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
    Falkenberg, Katrina J.
    Johnstone, Ricky W.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (09) : 673 - 691
  • [7] The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
    Geng, Leiluo
    Lam, Karen S. L.
    Xu, Aimin
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2020, 16 (11) : 654 - 667
  • [8] Role of epithelial to mesenchymal transition in hepatocellular carcinoma
    Giannelli, Gianluigi
    Koudelkova, Petra
    Dituri, Francesco
    Mikulits, Wolfgang
    [J]. JOURNAL OF HEPATOLOGY, 2016, 65 (04) : 798 - 808
  • [9] The Epigenetic Regulation of HCC Metastasis
    Han, Tae-Su
    Ban, Hyun Seung
    Hur, Keun
    Cho, Hyun-Soo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (12)
  • [10] G9a and histone deacetylases are crucial for Snail2-mediated E-cadherin repression and metastasis in hepatocellular carcinoma
    Hu, Yue
    Zheng, Yayuan
    Dai, Mingrui
    Wang, Xueju
    Wu, Jiaxin
    Yu, Bin
    Zhang, Haihong
    Cui, Yinqiu
    Kong, Wei
    Wu, Hui
    Yu, Xianghui
    [J]. CANCER SCIENCE, 2019, 110 (11) : 3442 - 3452